Pre-clinical evaluation of D2C7, a monoclonal antibody reactive for both the wild type and variant III mutant epidermal growth factor receptor, for radioimmunotherapy of malignant gliomas
Publication
, Conference
Boskovitz, A; Pegram, C; Peixoto, K; Zalutsky, MR; Bigner, DD
Published in: NEURO-ONCOLOGY
July 1, 2005
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
July 1, 2005
Volume
7
Issue
3
Start / End Page
370 / 370
Location
Edinburgh, SCOTLAND
Publisher
DUKE UNIV PRESS
Conference Name
2nd Quadrennial Meeting of the World-Federation-of-Neuro-Oncology/6th Meeting of the European-Association-for-Neur-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Boskovitz, A., Pegram, C., Peixoto, K., Zalutsky, M. R., & Bigner, D. D. (2005). Pre-clinical evaluation of D2C7, a monoclonal antibody reactive for both the wild type and variant III mutant epidermal growth factor receptor, for radioimmunotherapy of malignant gliomas. In NEURO-ONCOLOGY (Vol. 7, pp. 370–370). Edinburgh, SCOTLAND: DUKE UNIV PRESS.
Boskovitz, A., C. Pegram, K. Peixoto, M. R. Zalutsky, and D. D. Bigner. “Pre-clinical evaluation of D2C7, a monoclonal antibody reactive for both the wild type and variant III mutant epidermal growth factor receptor, for radioimmunotherapy of malignant gliomas.” In NEURO-ONCOLOGY, 7:370–370. DUKE UNIV PRESS, 2005.
Boskovitz A, Pegram C, Peixoto K, Zalutsky MR, Bigner DD. Pre-clinical evaluation of D2C7, a monoclonal antibody reactive for both the wild type and variant III mutant epidermal growth factor receptor, for radioimmunotherapy of malignant gliomas. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 370–370.
Boskovitz, A., et al. “Pre-clinical evaluation of D2C7, a monoclonal antibody reactive for both the wild type and variant III mutant epidermal growth factor receptor, for radioimmunotherapy of malignant gliomas.” NEURO-ONCOLOGY, vol. 7, no. 3, DUKE UNIV PRESS, 2005, pp. 370–370.
Boskovitz A, Pegram C, Peixoto K, Zalutsky MR, Bigner DD. Pre-clinical evaluation of D2C7, a monoclonal antibody reactive for both the wild type and variant III mutant epidermal growth factor receptor, for radioimmunotherapy of malignant gliomas. NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 370–370.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
July 1, 2005
Volume
7
Issue
3
Start / End Page
370 / 370
Location
Edinburgh, SCOTLAND
Publisher
DUKE UNIV PRESS
Conference Name
2nd Quadrennial Meeting of the World-Federation-of-Neuro-Oncology/6th Meeting of the European-Association-for-Neur-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences